Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Targacept down on pain data

TRGT fell $1.59 (17%) to $8.01 after TC-2696 missed

Read the full 97 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE